Greenwich LifeSciences expands Phase III Flamingo-01 arm to 250 patients; European sites pending

Greenwich LifeSciences, Inc.

DSMB recommended continue as is; no serious adverse events related to GLSI-100 reported to date.
Non-HLA-A*02 open-label arm expanded from 100 to 250 patients per Steering Committee guidance.
European regulatory approval expected 2024; contracts for 105-120 sites in Spain, France, Germany, Italy, Poland.
First 3 commercial lots of GP2 completed in 2023; enough for ~200,000 doses; commercial vial filling planned 2024.
Phase II data review found potential recurrence in treated arm (Q4 2023); company states no material effect on study power.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.